Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69).
作者信息
Watkins Claire, Rukazenkov Yuri
出版信息
J Cell Mol Med. 2010 Nov;14(11):2693-4. doi: 10.1111/j.1582-4934.2010.01188.x.
Abstract
摘要
相似文献
1
Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis'
(Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69).对《EGFR 突变的非小细胞肺癌患者的临床结局：汇总分析》的回应（帕兹 - 阿雷斯等人，《细胞与分子医学杂志》。2010 年；14：51 - 69）
J Cell Mol Med. 2010 Nov;14(11):2693-4. doi: 10.1111/j.1582-4934.2010.01188.x.
2
Reply to Watkins and Rukazenkov (J Cell Mol Med 2010), re-Letter of Response to manuscript entitled 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14(1-2): 51-69).对沃特金斯和鲁卡先科夫的回复（《细胞与分子医学杂志》，2010年），对题为“非小细胞肺癌表皮生长因子受体突变患者的临床结果：汇总分析”的稿件的回复信（帕斯-阿雷斯等人，《细胞与分子医学杂志》。2010年；14(1 - 2)：51 - 69）。
J Cell Mol Med. 2011 May;15(5):1225. doi: 10.1111/j.1582-4934.2011.01295.x.
3
New data highlighting the efficacy and safety outcomes of third-generation EGFR-TKI in NSCLC patients with rare EGFR mutations.新数据凸显了第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）在具有罕见EGFR突变的非小细胞肺癌（NSCLC）患者中的疗效和安全性结果。
Thorac Cancer. 2020 Mar;11(3):495-497. doi: 10.1111/1759-7714.13334. Epub 2020 Jan 28.
4
Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.晚期表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）患者的治疗：测序至关重要。
Pulmonology. 2019 Sep-Oct;25(5):306-309. doi: 10.1016/j.pulmoe.2019.04.005. Epub 2019 Jun 7.
5
Third-generation EGFR-TKIs—a new hope for NSCLC.第三代表皮生长因子受体酪氨酸激酶抑制剂——非小细胞肺癌的新希望。
Lancet Respir Med. 2014 Jul;2(7):520. doi: 10.1016/s2213-2600(14)70095-5.
6
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.表皮生长因子受体抑制剂作为表皮生长因子受体突变的可切除非小细胞肺癌的辅助治疗。
Lung Cancer. 2019 Oct;136:6-14. doi: 10.1016/j.lungcan.2019.08.001. Epub 2019 Aug 2.
7
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.非小细胞肺癌中的体细胞表皮生长因子受体（EGFR）突变与酪氨酸激酶抑制剂的疗效
Nat Rev Clin Oncol. 2009 Jun;6(6):352-66. doi: 10.1038/nrclinonc.2009.62.
8
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.阿法替尼用于奥希替尼耐药的EGFR外显子19缺失/T790M/P794L突变的非小细胞肺癌
J Thorac Oncol. 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25.
9
Does EGFR targeted therapy change the natural history of EGFR mutant status?表皮生长因子受体（EGFR）靶向治疗会改变EGFR突变状态的自然病程吗？
J BUON. 2017 Mar-Apr;22(2):560-561.
10
Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.简短报告：伴有柔脑膜癌病的EGFR L833V/H835L双突变非小细胞肺癌对奥希替尼有反应
Clin Lung Cancer. 2023 Jun;24(4):360-361. doi: 10.1016/j.cllc.2023.01.010. Epub 2023 Feb 9.
本文引用的文献
1
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
2
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者（WJTOG3405）：一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.
3
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.非小细胞肺癌患者表皮生长因子受体突变的临床结局：汇总分析。
J Cell Mol Med. 2010 Jan;14(1-2):51-69. doi: 10.1111/j.1582-4934.2009.00991.x. Epub 2009 Dec 8.
4
Screening for epidermal growth factor receptor mutations in lung cancer.肺癌中表皮生长因子受体突变的筛查
N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.
5
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
6
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.表皮生长因子受体基因及相关基因的突变作为肺癌中表皮生长因子受体酪氨酸激酶抑制剂敏感性的决定因素
Cancer Sci. 2007 Dec;98(12):1817-24. doi: 10.1111/j.1349-7006.2007.00607.x. Epub 2007 Sep 20.
7
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.表皮生长因子受体中的激活突变是非小细胞肺癌对吉非替尼产生反应的基础。
N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
Zotero 插件